Company intelligence / Profile preview

CalAsia Pharmaceuticals

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Early-stage biotech with pre-clinical small molecule leads for protein misfolding diseases; advanced lead for neurofibromatosis type-2 aimed at IND-ready by 2016; funded by NIH and MJFF grants.

Therapeutic areas: OphthalmologyOncologyNeurologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Michael J. Fox FoundationCollidion Inc. (80% equity stake acquired in 2017)

Beyond the preview

Go deeper on CalAsia Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CalAsia Pharmaceuticals.

Explore the full profile